Kassem M - Search Results

1

Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.

Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ. Imel EA, et al. Among authors: kassem m. J Clin Endocrinol Metab. 2006 Jun;91(6):2055-61. doi: 10.1210/jc.2005-2105. Epub 2006 Mar 21. J Clin Endocrinol Metab. 2006. PMID: 16551733 Free article.

2

Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.

Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Parkinson C, et al. Among authors: kassem m. J Clin Endocrinol Metab. 2003 Dec;88(12):5650-5. doi: 10.1210/jc.2003-030772. J Clin Endocrinol Metab. 2003. PMID: 14671148 Clinical Trial.

3

[Fibroblast growth factor 23--a phosphate regulating hormone].

Beck-Nielsen SS, Pedersen SM, Kassem M, Rasmussen LM. Beck-Nielsen SS, et al. Among authors: kassem m. Ugeskr Laeger. 2010 May 17;172(20):1521-7. Ugeskr Laeger. 2010. PMID: 20483099 Review. Danish.

4

Transforming growth factor-beta1 stimulates the production of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in human bone marrow stromal osteoblast progenitors.

Kveiborg M, Flyvbjerg A, Eriksen EF, Kassem M. Kveiborg M, et al. Among authors: kassem m. J Endocrinol. 2001 Jun;169(3):549-61. doi: 10.1677/joe.0.1690549. J Endocrinol. 2001. PMID: 11375125

5

Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women.

Kassem M, Brixen K, Mosekilde L, Blum WF, Flyvbjerg A. Kassem M, et al. Clin Endocrinol (Oxf). 1998 Dec;49(6):747-56. doi: 10.1046/j.1365-2265.1998.00606.x. Clin Endocrinol (Oxf). 1998. PMID: 10209562 Clinical Trial.

6

[Biological action mechanisms and effects of calcitriol].

Kveiborg M, Mosekilde L, Eriksen EF, Kassem MS. Kveiborg M, et al. Among authors: kassem ms. Ugeskr Laeger. 1999 Oct 11;161(41):5669-74. Ugeskr Laeger. 1999. PMID: 10565236 Review. Danish.

7

[Mesenchymal stem cell therapy--the key to regenerative medicine?].

Kassem M, Kastrup J, Olsen G, Johnsen HE. Kassem M, et al. Ugeskr Laeger. 2003 Dec 8;165(50):4852-5. Ugeskr Laeger. 2003. PMID: 14716904 Review. Danish. No abstract available.

8

[Stem cell therapy in ischemic heart disease].

Diederichsen AC, Møller JE, Kristiansen MA, Saekmose SG, Barington T, Videbaek LM, Kassem MS, Thayssen P. Diederichsen AC, et al. Among authors: kassem ms. Ugeskr Laeger. 2006 Mar 13;168(11):1111-4. Ugeskr Laeger. 2006. PMID: 16545213 Review. Danish.

9

Dlk1/FA1 is a novel endocrine regulator of bone and fat mass and its serum level is modulated by growth hormone.

Abdallah BM, Ding M, Jensen CH, Ditzel N, Flyvbjerg A, Jensen TG, Dagnaes-Hansen F, Gasser JA, Kassem M. Abdallah BM, et al. Among authors: kassem m. Endocrinology. 2007 Jul;148(7):3111-21. doi: 10.1210/en.2007-0171. Epub 2007 Apr 19. Endocrinology. 2007. PMID: 17446189

10

[Bone and cartilage repair using stem cells].

Larsen KH, Andersen TE, Kassem M. Larsen KH, et al. Among authors: kassem m. Ugeskr Laeger. 2010 Sep 20;172(38):2616-9. Ugeskr Laeger. 2010. PMID: 20920407 Review. Danish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

672 results

Search Page